Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Future treatment landscape for sarcoma

Rimas J. Orentas, PhD, Seattle Children’s Research Institute, Seattle, WA, shares his thoughts on how the treatment landscape for sarcoma will evolve over the next few years, highlighting the impacts of epigenetic regulation on treatment and the potential of epigenetic modifiers. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.


Rimas J. Orentas, PhD, has received research support from Lentigen, a Miltenyi Biotec Company; and has participated in a consultancy role for Umoja Biopharma.